Haldol Dec 50 Mg

Content:
  • Mylan Worldwide
  • Haldol, Haldol Decanoate (haloperidol) dosing, indications, interactions, adverse effects, and more
  • HALDOL DECANOATE INJ (Haloperidol) dosage, indication, interactions, side effects | EMPR
  • Haldol

    Mylan Worldwide

    haldol dec 50 mg A multidose study of haloperidol decanoate in the maintenance treatment of haldol dec 50 mg. Am J Psychiatry Apr ; In patients with haldol dec 50 mg, what are the rates of symptomatic exacerbation and adverse effects with 4 different doses of haloperidol decanoate? Exclusion criteria were treatment with lithium or antidepressants, women of childbearing potential not using acceptable birth control methods, contraindications to haloperidol use, or a Brief Psychiatric Rating Scale BPRS score above a specific threshold on any of 4 psychotic items. All previous antipsychotic medication was discontinued before entry into study. Rates of symptomatic exacerbations and adverse events.

    Haldol, Haldol Decanoate (haloperidol) dosing, indications, interactions, adverse effects, and more

    haldol dec 50 mg

    A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry Apr ; In patients with schizophrenia, what are the rates of symptomatic exacerbation and adverse effects with 4 different doses of haloperidol decanoate? Exclusion criteria were treatment with lithium or antidepressants, women of childbearing potential not using acceptable birth control methods, contraindications to haloperidol use, or a Brief Psychiatric Rating Scale BPRS score above a specific threshold on any of 4 psychotic items.

    All previous antipsychotic medication was discontinued before entry into study. Rates of symptomatic exacerbations and adverse events. Among patients having no symptomatic exacerbation who remained in the study for 1 year, no difference existed among groups on any psychopathology measure at 1 year. No difference existed among groups for rates of study withdrawal because of adverse effects. Although several studies have compared the efficacy and tolerability of different dosages of antipsychotic medications for psychotic relapses, this has been addressed in few relapse prevention studies, and none compared various dosages of haloperidol.

    Thus, the study by Kane et al is relevant for clinical practice. The use of a randomised double blind design makes this study appropriate to answer the research question. Firstly, probably because of the small sample size, minor differences were seen among groups before randomisation, but confounding was prevented using appropriate covariance analyses.

    Secondly, the modest sample size may have limited power to find differences among the 3 higher dosage groups. Thirdly, the assessment of side effects was not detailed, and the study duration, although longer than usual efficacy studies, was still relatively short to assess some side effects eg, tardive dyskinesia.

    Thus, the lack of differences in tolerability among the dosages should be interpreted cautiously. The patients sampled are probably representative of those who are offered antipsychotics; however, 3 issues must be considered to assess generalisability. Firstly, patients included in such efficacy studies probably represent a subgroup of relatively cooperative patients who are not totally representative of the patients for whom such medications are used.

    Secondly, because most patients were men, the sex specificity of these results are not addressed. Thirdly, because patients had a relatively long duration of illness, the extent to which the conclusions apply to patients with more recent onset schizophrenia is unknown.

    Using a higher dosage appears warranted. However, because none of the relapses justified a hospital admission, if side effects occur, cautious dosage reduction done under close medical supervision may be relatively safe. You will be able to get a quick price and instant permission to reuse the content in many different ways. Skip to main content. This site uses cookies. More info By continuing to browse the site you are agreeing to our use of cookies.

    Find out more here. Log in via OpenAthens. Log in using your username and password For personal accounts OR managers of institutional accounts. Forgot your log in details? Register a new account? Forgot your user name or password? Search for this keyword. Latest content Current issue Archive Authors About. Log in via Institution. Setting 6 sites in the US. Main outcome measures Rates of symptomatic exacerbations and adverse events.

    View inline View popup. Copyright by the Evidence-Based Mental Health. Read the full text or download the PDF:

    HALDOL DECANOATE INJ (Haloperidol) dosage, indication, interactions, side effects | EMPR

    haldol dec 50 mg

    haldol dec 50 mg

    haldol dec 50 mg